Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here.
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
LimFlow raises $40 million (€36 million) in Series D financing
Redx nominates GI-targeted ROCK Inhibitor, RXC008, as clinical development candidate
The secrets to 50 years of success in life sciences investment
Abivax reports promising ABX464 phase 2A one-year maintenance results in rheumatoid arthritis